vs

Side-by-side financial comparison of AMES NATIONAL CORP (ATLO) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $18.7M, roughly 1.1× AMES NATIONAL CORP). AMES NATIONAL CORP runs the higher net margin — 34.9% vs -66.3%, a 101.2% gap on every dollar of revenue. On growth, AMES NATIONAL CORP posted the faster year-over-year revenue change (26.7% vs -8.7%). Over the past eight quarters, AMES NATIONAL CORP's revenue compounded faster (19.5% CAGR vs -0.5%).

Ames National Corp is a U.S. financial holding company based in Iowa. It operates multiple community banking subsidiaries, offering retail and commercial financial services including deposit accounts, personal and business loans, mortgages, and wealth management, primarily serving consumers and SMEs across central Iowa.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

ATLO vs LUNG — Head-to-Head

Bigger by revenue
LUNG
LUNG
1.1× larger
LUNG
$20.6M
$18.7M
ATLO
Growing faster (revenue YoY)
ATLO
ATLO
+35.3% gap
ATLO
26.7%
-8.7%
LUNG
Higher net margin
ATLO
ATLO
101.2% more per $
ATLO
34.9%
-66.3%
LUNG
Faster 2-yr revenue CAGR
ATLO
ATLO
Annualised
ATLO
19.5%
-0.5%
LUNG

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ATLO
ATLO
LUNG
LUNG
Revenue
$18.7M
$20.6M
Net Profit
$6.5M
$-13.7M
Gross Margin
77.9%
Operating Margin
44.3%
-40.9%
Net Margin
34.9%
-66.3%
Revenue YoY
26.7%
-8.7%
Net Profit YoY
85.4%
5.5%
EPS (diluted)
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATLO
ATLO
LUNG
LUNG
Q1 26
$20.6M
Q4 25
$18.7M
$22.6M
Q3 25
$16.6M
$21.5M
Q2 25
$16.1M
$23.9M
Q1 25
$15.5M
$22.5M
Q4 24
$14.7M
$23.8M
Q3 24
$13.5M
$20.4M
Q2 24
$13.5M
$20.8M
Net Profit
ATLO
ATLO
LUNG
LUNG
Q1 26
$-13.7M
Q4 25
$6.5M
$-10.4M
Q3 25
$4.6M
$-14.0M
Q2 25
$4.5M
$-15.2M
Q1 25
$3.4M
$-14.4M
Q4 24
$3.5M
$-13.2M
Q3 24
$2.2M
$-14.1M
Q2 24
$2.2M
$-15.3M
Gross Margin
ATLO
ATLO
LUNG
LUNG
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
ATLO
ATLO
LUNG
LUNG
Q1 26
-40.9%
Q4 25
44.3%
-43.8%
Q3 25
34.5%
-66.9%
Q2 25
35.0%
-62.0%
Q1 25
27.4%
-64.6%
Q4 24
29.4%
-56.5%
Q3 24
19.4%
-69.3%
Q2 24
19.0%
-75.2%
Net Margin
ATLO
ATLO
LUNG
LUNG
Q1 26
-66.3%
Q4 25
34.9%
-46.1%
Q3 25
27.5%
-64.9%
Q2 25
28.0%
-63.6%
Q1 25
22.3%
-64.1%
Q4 24
23.8%
-55.4%
Q3 24
16.4%
-69.4%
Q2 24
16.2%
-73.7%
EPS (diluted)
ATLO
ATLO
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$-0.25
Q3 25
$-0.34
Q2 25
$-0.38
Q1 25
$-0.36
Q4 24
$-0.33
Q3 24
$-0.36
Q2 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATLO
ATLO
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$126.8M
$61.6M
Total DebtLower is stronger
$18.4M
$37.3M
Stockholders' EquityBook value
$207.9M
$45.8M
Total Assets
$2.1B
$120.0M
Debt / EquityLower = less leverage
0.09×
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATLO
ATLO
LUNG
LUNG
Q1 26
$61.6M
Q4 25
$126.8M
$69.8M
Q3 25
$108.2M
$76.5M
Q2 25
$95.2M
$75.5M
Q1 25
$163.4M
$74.6M
Q4 24
$101.2M
$70.9M
Q3 24
$59.0M
$63.3M
Q2 24
$63.4M
$63.5M
Total Debt
ATLO
ATLO
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$18.4M
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$20.0M
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
ATLO
ATLO
LUNG
LUNG
Q1 26
$45.8M
Q4 25
$207.9M
$54.1M
Q3 25
$200.6M
$60.0M
Q2 25
$193.0M
$69.1M
Q1 25
$183.1M
$77.7M
Q4 24
$174.7M
$85.8M
Q3 24
$183.4M
$93.9M
Q2 24
$167.1M
$101.2M
Total Assets
ATLO
ATLO
LUNG
LUNG
Q1 26
$120.0M
Q4 25
$2.1B
$129.3M
Q3 25
$2.1B
$138.3M
Q2 25
$2.1B
$147.2M
Q1 25
$2.2B
$150.7M
Q4 24
$2.1B
$162.8M
Q3 24
$2.1B
$167.4M
Q2 24
$2.1B
$172.6M
Debt / Equity
ATLO
ATLO
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.09×
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.11×
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATLO
ATLO
LUNG
LUNG
Operating Cash FlowLast quarter
$21.3M
Free Cash FlowOCF − Capex
$20.7M
FCF MarginFCF / Revenue
110.8%
Capex IntensityCapex / Revenue
3.4%
Cash ConversionOCF / Net Profit
3.28×
TTM Free Cash FlowTrailing 4 quarters
$34.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATLO
ATLO
LUNG
LUNG
Q1 26
Q4 25
$21.3M
$-7.1M
Q3 25
$2.8M
$-8.2M
Q2 25
$4.0M
$-3.9M
Q1 25
$7.1M
$-13.2M
Q4 24
$14.3M
$-6.7M
Q3 24
$3.1M
$-7.2M
Q2 24
$3.9M
$-5.8M
Free Cash Flow
ATLO
ATLO
LUNG
LUNG
Q1 26
Q4 25
$20.7M
$-7.1M
Q3 25
$2.6M
$-8.3M
Q2 25
$3.9M
$-4.0M
Q1 25
$6.9M
$-13.5M
Q4 24
$14.0M
$-6.8M
Q3 24
$3.0M
$-7.7M
Q2 24
$3.8M
$-6.2M
FCF Margin
ATLO
ATLO
LUNG
LUNG
Q1 26
Q4 25
110.8%
-31.4%
Q3 25
16.0%
-38.4%
Q2 25
24.2%
-16.6%
Q1 25
44.8%
-60.0%
Q4 24
94.9%
-28.8%
Q3 24
22.5%
-37.6%
Q2 24
28.1%
-30.0%
Capex Intensity
ATLO
ATLO
LUNG
LUNG
Q1 26
Q4 25
3.4%
0.1%
Q3 25
0.6%
0.4%
Q2 25
0.7%
0.2%
Q1 25
1.3%
1.3%
Q4 24
2.0%
0.5%
Q3 24
0.5%
2.0%
Q2 24
0.7%
2.3%
Cash Conversion
ATLO
ATLO
LUNG
LUNG
Q1 26
Q4 25
3.28×
Q3 25
0.60×
Q2 25
0.89×
Q1 25
2.07×
Q4 24
4.07×
Q3 24
1.40×
Q2 24
1.78×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons